Livzon Pharmaceutical
丽珠集团
Executive Summary
Livzon Pharmaceutical is a Zhuhai-based Chinese pharma company (000513.SZ) with clear BIOSECURE status, generating RMB 9.08B revenue and RMB 1.67B net profit as of 2024. The company is actively pursuing international expansion through M&A, including a public tender offer for Vietnamese company IMP, suggesting an outward-looking BD posture. Recent management changes and board resolutions indicate potential strategic shifts that could create partnering opportunities for US pharma companies.
Structure: Livzon operates as a publicly-listed Chinese pharmaceutical group on the Shenzhen Stock Exchange with both A-shares and H-shares, indicating access to both domestic and Hong Kong capital markets. The company maintains subsidiaries requiring parent guarantees, suggesting a traditional holding company structure rather than complex VIE arrangements, which should simplify due diligence processes.
Latest Financials
Revenue: 9081603788.36, Net Profit: 1672733989.63. Source: East Money (000513)
Period: 2024-09-30 | Source: eastmoney
Corporate Events
丽珠集团：关于公开要约收购越南IMP公司股权的进展公告
CNINFO announcement for Livzon Pharmaceutical (000513.SZ)
丽珠集团：H股公告：证券变动月报表
CNINFO announcement for Livzon Pharmaceutical (000513.SZ)
丽珠集团：关于为子公司提供担保的进展公告
CNINFO announcement for Livzon Pharmaceutical (000513.SZ)
丽珠集团：关于部分董事、高级管理人员变更的公告
CNINFO announcement for Livzon Pharmaceutical (000513.SZ)
丽珠集团：第十一届董事会第三十二次会议决议公告
CNINFO announcement for Livzon Pharmaceutical (000513.SZ)
Livzon Pharmaceutical Financial Report
Revenue: 9081603788.36, Net Profit: 1672733989.63. Source: East Money (000513)
BIOSECURE Risk
Company has clear BIOSECURE status with no BCC designation, indicating minimal regulatory risk for US partnerships
Key Exposures:
- •Potential indirect exposure through undisclosed subsidiary relationships
- •Future policy changes affecting all Chinese pharma entities
Mitigation: Currently maintains clear status but specific mitigation strategies are not publicly disclosed
BD Intelligence
Therapeutic Areas:
Recent Deals: Active in outbound M&A with ongoing public tender offer for Vietnamese IMP company, suggesting capital availability and international expansion strategy
Approach: Approach through senior management given recent leadership changes; focus on licensing opportunities that support their international expansion strategy
Red Flags
- ⚠Recent management turnover could indicate strategic uncertainty
- ⚠Limited public disclosure of pipeline and therapeutic focus areas
- ⚠Subsidiary guarantee requirements suggest potential financial interdependencies
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 6
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.